Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: needawin who wrote (1368)	1/30/1998 9:06:00 PM
From: Rajendra KRISHNAN	Respond to of 2205

All, Like Marshall says now and then - if you're in this for the long haul, you wont much bother about the fluctuations as we saw today. Keep the faith and be patient and you are sure to be well rewarded ! R Krishnan

To: needawin who wrote (1368)	1/30/1998 9:23:00 PM
From: John M. McCann	Read Replies (2) \| Respond to of 2205

Morgan Stanley has had a buy recommendation in place with a target price of $20/sh. Doug Lind, M.D. is the following analyst and he issued a company update today raising his price target to $25! He still expects final approval by mid-"98 and has revenue projections for ATIS/Smith & Newphew for Dermagraft of $39 million in '98, $103 mill in "99 and $239 Mill in 2000. He's looking for a slower initial market penetration than previous but once confidence in the treatment increases, he looks for accelerated penetration. This led him to lower EPS for '98, '99 ' 2000 to $(.51), $(.05) and $1.04 from $(.19), $0.45 and $1.46. Additionally, he looks for pilot trials in venous ulcers in 1st half of '98, and a number of foreign market launches befor the end of the year. ATIS release also mentions the anticipated start of human trials involving cartilege by year end. Expect a modest price improvement with much emphasis on the $500 mill capitalization by the shorts trying to hold prices down. I would be anxious to hear what Megan Hoe at Goldman Sachs has to say (she has a current BUY rating looking to $20+, and I know David Webber at Pincus Warburg is still the biggest bull around. (Had a price target of $32 last time I was in touch). I would look forward to any change in opinion by him. Best regards to all, Jack